{"title":"Therapeutic applications of drug coated balloons in symptomatic intracranial arterial stenosis: systematic review and quantitative meta-analysis.","authors":"Ying Tao, Dunming Xiao, Yingyao Chen, Shimeng Liu","doi":"10.1136/jnis-2024-022878","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Intracranial atherosclerotic stenosis (ICAS) represents a major cause of ischemic stroke, with endovascular treatments, such as stenting, facing challenges such as restenosis and complications. Drug coated balloons (DCBs) provide a promising alternative by delivering targeted drug without permanent implants. This review systematically evaluates the efficacy and safety of DCBs for symptomatic ICAS, providing evidence based insights to guide clinical practice.</p><p><strong>Methods: </strong>Databases were searched from inception to October 16, 2023, to identify studies on DCBs for symptomatic ICAS. Two independent researchers screened the literature and extracted data. A meta-analysis was performed using the Freeman-Tukey double arcsine transformation with random or fixed effects models to assess perioperative safety and restenosis rates. Heterogeneity and publication bias were also evaluated.</p><p><strong>Results: </strong>The analysis included six controlled studies and 16 single arm studies involving 1308 patients with ≥70% stenosis. In single arm studies, the pooled restenosis rate for DCBs was 7.34% (95% CI 0.05 to 0.10, I²=44%, P=0.04), with a perioperative stroke and mortality rate of 5.75% (95% CI 0.04 to 0.08, I²=25%, P=0.18). The follow-up stroke and transient ischemic attack rate was 1.26% (95% CI 0.00 to 0.03, I²=33%, P=0.11). In controlled studies, DCBs significantly reduced restenosis rates compared with conventional balloons (OR=0.24, P=0.003) and stents (OR=0.20, P<0.001), without increasing perioperative adverse events.</p><p><strong>Conclusions: </strong>In this study, DCBs showed significant potential as an effective therapeutic option for symptomatic ICAS in clinical practice, offering lower restenosis rates compared with conventional endovascular approaches while maintaining comparable safety profiles. However, further larger scale, high quality prospective studies are essential to validate these findings and establish standardized protocols for their application.</p>","PeriodicalId":16411,"journal":{"name":"Journal of NeuroInterventional Surgery","volume":" ","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of NeuroInterventional Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/jnis-2024-022878","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROIMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Intracranial atherosclerotic stenosis (ICAS) represents a major cause of ischemic stroke, with endovascular treatments, such as stenting, facing challenges such as restenosis and complications. Drug coated balloons (DCBs) provide a promising alternative by delivering targeted drug without permanent implants. This review systematically evaluates the efficacy and safety of DCBs for symptomatic ICAS, providing evidence based insights to guide clinical practice.
Methods: Databases were searched from inception to October 16, 2023, to identify studies on DCBs for symptomatic ICAS. Two independent researchers screened the literature and extracted data. A meta-analysis was performed using the Freeman-Tukey double arcsine transformation with random or fixed effects models to assess perioperative safety and restenosis rates. Heterogeneity and publication bias were also evaluated.
Results: The analysis included six controlled studies and 16 single arm studies involving 1308 patients with ≥70% stenosis. In single arm studies, the pooled restenosis rate for DCBs was 7.34% (95% CI 0.05 to 0.10, I²=44%, P=0.04), with a perioperative stroke and mortality rate of 5.75% (95% CI 0.04 to 0.08, I²=25%, P=0.18). The follow-up stroke and transient ischemic attack rate was 1.26% (95% CI 0.00 to 0.03, I²=33%, P=0.11). In controlled studies, DCBs significantly reduced restenosis rates compared with conventional balloons (OR=0.24, P=0.003) and stents (OR=0.20, P<0.001), without increasing perioperative adverse events.
Conclusions: In this study, DCBs showed significant potential as an effective therapeutic option for symptomatic ICAS in clinical practice, offering lower restenosis rates compared with conventional endovascular approaches while maintaining comparable safety profiles. However, further larger scale, high quality prospective studies are essential to validate these findings and establish standardized protocols for their application.
期刊介绍:
The Journal of NeuroInterventional Surgery (JNIS) is a leading peer review journal for scientific research and literature pertaining to the field of neurointerventional surgery. The journal launch follows growing professional interest in neurointerventional techniques for the treatment of a range of neurological and vascular problems including stroke, aneurysms, brain tumors, and spinal compression.The journal is owned by SNIS and is also the official journal of the Interventional Chapter of the Australian and New Zealand Society of Neuroradiology (ANZSNR), the Canadian Interventional Neuro Group, the Hong Kong Neurological Society (HKNS) and the Neuroradiological Society of Taiwan.